DRREDDY Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > drreddy

Technical Analysis

Technical Strength: 8.1 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 65.6. According to RSI analysis, drreddy is technically strong. 9.0 DRREDDY RSI Chart
MACD (?) MACD: 72.9 and Signal Line: 72.2. According to MACD analysis, a bullish crossover just happend and it's a positive signal. But note that MACD is already positive. 8.0 DRREDDY MACD Chart
Simple Moving Average (?) According to simple moving average analysis, drreddy is in a strong uptrend. Major support levels are 3850.052, 3568.898, 3035.245. 10.0 DRREDDY Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, drreddy is in a strong uptrend. Major support levels are 3841.836, 3648.95, 3160.686. 10.0 DRREDDY Exponential Moving Average Chart
Bollinger Bands (?) %b is 1.08. According to bollinger bands, drreddy is technically strong. 7.0 DRREDDY Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 3506.8087 and 3313.625. Resistance level is 4132.2. 6.5 DRREDDY Fibonacci Retracement Chart
Average True Range (?) ATR: 138 NA DRREDDY Average True Range Chart
Average Directional Index (?) ADX is 32.1 which means DRREDDY is in a trend. NA DRREDDY Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
May 29, 2020
Open Price 3880.0
High Price 4090.7
Low Price 3869.3
Close Price 4071.25
Absolute Change 183.5
Percentage Change 4.72%
Weekly Change 5.82%
Monthly Change 4.91%
Yearly Change 57.2%
52-week high 4132.2
52-week low 2351.2
Corporate Actions
ExDate Purpose
July 15, 2019 AGM/DIV-RS 20 PER SH
July 16, 2018 AGM/DIV-RS 20 PER SHARE
July 17, 2017 Annual General Meeting/Dividend - Rs 20/- Per Share
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.498
Confidence in Beta1.83%
Market Capital Rs. 69365.0 Cr
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 29 May 2020: Deliverable Quantity:5.86e+05 NA DRREDDY Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 29 May 2020: Daily Volatility:0.4967 NA DRREDDY Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 29 May 2020: PCR_OI:0.588 PCR:0.194 NA DRREDDY PCR Chart
Option Pain (?) 29 May 2020: Max Pain:3900.0 NA DRREDDY Option Pain Chart
Premium (?) 29 May 2020 Premium: -38.8 Futures OI:3056750.0 NA DRREDDY Premium Chart
Option_MAX_OI (?) 29 May 2020: Price:4071.25 Put with maximum OI:3800.0 Call with maximum OI:4000.0 NA DRREDDY Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
June 25, 2020 4032.45 3056750.0 11176.0 11176.0 4071.25
July 30, 2020 4019.2 17000.0 106.0 106.0 4071.25
August 27, 2020 3935.55 0.0 0.0 0.0 4071.25

Announcements

May 15, 2019 News Clarification DRREDDY: The Exchange had sought clarification from the Company with respect to news item captioned- titled "Pharma stocks bleed as US states file lawsuit against generic drug firms". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following: a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order. b) The material impact of this article on the Company. c) Whether company was aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations. The response from the Company is attached.
October 23, 2018 Reply to Clarification Sought DRREDDY:The Exchange had sought clarification from Dr. Reddy's Laboratories Limited with respect to announcement dated 15-Oct-2018, regarding regarding a press release dated October 15, 2018, titled "Dr. Reddy's Laboratories announces the sale of its API manufacturing business unit in Jeedimetla, Hyderabad ".". On basis of above the Company is required to clarify following: 1. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.
See all Announcements

Board Meetings

Date Meeting Date Purpose
March 30, 2020 May 13, 2020 Financial Results/Dividend To consider and approve the financial results for the period ended March 31, 2020 and dividend
March 24, 2020 March 27, 2020 Fund Raising To consider fund raising through issuance of Commercial Papers
See all Board Meetings

DRREDDY is part of...

Index Weightage
CNXPHARMA NA

Get Clearnifty's Android App.

Get clearnifty on Google Play
Get clearnifty on Google Play